CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2003-07-30): Hepatitis C coinfection hampers benefits of HAART in HIV patients


Hepatitis C coinfection hampers benefits of HAART in HIV patients

Last Updated: 2003-07-30 15:01:16 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Despite undergoing highly active antiretroviral therapy (HAART), patients infected with both hepatitis C virus (HCV) and HIV are at increased risk of hospitalization and death, Canadian researchers report in the July 1st issue of the Journal of Acquired Immune Deficiency Syndromes

As lead investigator Dr. Marina B. Klein told Reuters Health, "Hepatitis C coinfection, along with other associated factors such as injection drug use, have prevented such individuals from realizing the substantial health gains brought about by HAART."

Dr. Klein and colleagues at McGill University Health Centre, Montreal, initially hypothesized that "it is quite likely that HCV-coinfected patients may not have derived equal benefit from the revolution brought about by HAART."

To investigate, the researchers conducted a retrospective cohort study covering the eras before and after the introduction of HAART. In total, 125 HCV-positive patients, 83% of whom were injection drug users, were involved, as were 1076 HCV-negative patients.

Altogether, say the investigators, the HCV-coinfected patients "experienced no clear benefit from HAART." Compared to the pre-HAART era, post-HAART adjusted hazard ratios for opportunistic infections were 0.74, for hospitalization 2.1, and for death 1.78.

In contrast, corresponding figures for HCV negative patients were 0.49, 0.51 and 0.28.

The researchers also note that deaths and hospitalizations in HCV-positive patients "were primarily for non-AIDS-defining infections and complications of injection drug use."

Summing up, Dr. Klein said, "The main conclusion that we drew from our research is that unless hepatitis C infection and associated behaviors are directly dealt with, coinfected patients will continue to suffer significant rates of illness and death that might be otherwise preventable."

J Acquir Immune Defic Syndr 2003;33:365-372.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Live CME Meetings
Slide Library
Abstract Library
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Substance Use Disorder
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2015 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.